Fertility is the most emotionally charged topic in women's health, and the peptide space exploits that vulnerability. Claims range from the genuinely evidence-based to the outright fabricated, and the difference is not always obvious when you are desperate and searching at 2 AM.
This article is a filter. It separates the peptides with real fertility-relevant evidence from those being marketed on hope alone. The bar is simple: what does the peer-reviewed literature actually support?
The Fertility Peptide Landscape
Peptides interact with fertility through several distinct mechanisms. Some target the hypothalamic-pituitary-gonadal axis directly. Some improve the metabolic environment that supports ovulation. Some may affect uterine receptivity or egg quality. And some are being sold with fertility claims that have no supporting evidence whatsoever.
The distinction matters because “peptides for fertility” is not a single category. It is a collection of compounds with very different mechanisms, evidence bases, and risk profiles.
Kisspeptin: Real Clinical Evidence
Kisspeptin has the strongest and most direct fertility evidence of any peptide. It is the master regulator of GnRH secretion, which controls the LH surge required for ovulation. Clinical trials at Imperial College London have demonstrated that kisspeptin-54 can trigger egg maturation in IVF with dramatically reduced risk of ovarian hyperstimulation syndrome.
For women with PMOS specifically, kisspeptin administration has induced LH responses and rescued ovulation in a subset of patients. The kisspeptin receptor agonist MVT-602 showed prolonged activity in women with PMOS, confirming that the pathway remains functionally responsive even when dysregulated.
Kisspeptin is still investigational for fertility indications. It is not FDA-approved for this use. But the mechanism is direct, the clinical data is from rigorous trials, and the potential to transform IVF trigger protocols is real.
GLP-1s: Indirect but Powerful
GLP-1 receptor agonists do not target the reproductive axis directly. They improve the metabolic conditions that support fertility. For women with PMOS and obesity, this distinction is almost academic because the metabolic dysfunction is the primary barrier to ovulation.
A 2023 study found that 63 percent of obese PMOS patients restored regular menstrual cycles within six months on semaglutide, compared to 12 percent with diet alone. Ovulation resumed in many women before significant weight loss occurred, suggesting direct metabolic effects beyond calorie reduction.
Some reproductive endocrinologists are now using GLP-1 therapy as a pre-IVF metabolic optimization strategy, improving insulin sensitivity and reducing body weight before fertility treatment begins.
The critical limitation: GLP-1s must be stopped at least two months before attempting conception. They are not safe during pregnancy. This means GLP-1 therapy is a pre-conception tool, not a concurrent fertility treatment.
Growth Hormone Peptides: The IVF Angle
Growth hormone (GH) co-treatment during IVF is an established practice for poor responders. Several studies show that GH supplementation improves oocyte yield, embryo quality, and pregnancy rates in women who respond poorly to standard stimulation protocols.
GH secretagogues like CJC-1295/Ipamorelin stimulate endogenous GH release. The theoretical application is to use GH peptides as a less expensive alternative to recombinant GH during IVF preparation. However, clinical trials specifically using GH peptides (rather than recombinant GH) for IVF optimization are lacking.
The evidence supports GH as a concept for IVF poor responders. The evidence does not yet support GH secretagogue peptides specifically for this application. The distinction matters.
BPC-157: The Endometrial Theory
BPC-157's angiogenic properties have led to speculation that it could improve uterine blood flow and endometrial receptivity. Thin endometrial lining is a common cause of implantation failure in IVF, and therapies that improve uterine blood supply are actively sought.
The mechanism is plausible. BPC-157 promotes VEGF-mediated angiogenesis. But there are zero studies, even preclinical, examining BPC-157's effects on endometrial thickness or receptivity. This is a hypothesis, not evidence. Do not choose BPC-157 for fertility based on theoretical angiogenesis.
The Snake Oil Tier
Several peptides are marketed with fertility claims that have no supporting evidence:
Epithalon for egg quality: Epithalon is a telomerase activator studied for anti-aging. There is no evidence it affects oocyte quality. The claim that longer telomeres equal better eggs is an oversimplification that does not hold up.
PT-141 for fertility: PT-141 (bremelanotide) is FDA-approved for hypoactive sexual desire disorder. It affects libido, not fertility. Having desire and having ovulation are different biological processes.
Generic “fertility peptide blends”: Any vendor selling a pre-mixed “fertility peptide” without specifying exact compounds and doses should be avoided. These are marketing products, not research tools.
An Honest Evidence Tier List
Tier 1 — Direct evidence in fertility contexts: Kisspeptin (IVF trigger, ovulation induction in PMOS). Strong human clinical data.
Tier 2 — Strong indirect evidence: GLP-1 RAs (metabolic optimization restoring ovulation). Multiple RCTs in PMOS. Recombinant GH (IVF poor responders). Established clinical practice.
Tier 3 — Plausible mechanism, no fertility-specific data: GH secretagogue peptides (CJC-1295/Ipa). BPC-157 (endometrial angiogenesis theory). MOTS-C (metabolic improvement).
Tier 4 — No evidence, marketed on hope: Epithalon for egg quality. PT-141 for fertility. Generic fertility blends.
Read the deep dive on kisspeptin's ovulation mechanism.
Kisspeptin Article →